Mutated trimeric RBD vaccines:a platform against variants of concern  

作　　者：Belén Aparicio Juan J.Lasarte Pablo Sarobe 

机构地区：[1]Programa de Inmunología e Inmunoterapia,Centro de Investigación Médica Aplicada(CIMA,CCUN),Universidad de Navarra,Pamplona,31008,Spain [2]Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas(CIBEREHD),Pamplona,31008,Spain [3]IdiSNA,Instituto de Investigación Sanitaria de Navarra,Pamplona,31008,Spain

出　　处：《Signal Transduction and Targeted Therapy》2023年第5期2038-2040,共3页信号转导与靶向治疗（英文）

基　　金：supported by Instituto de Salud Carlos III,Fondo Europeo de Desarrollo Regional"Una manera de hacer Europa"under grant PI20/00260,Gobierno de Navarra under grant 0011-3597-2020-000024 to PS and by Paula&Rodger Riney Foundation to JJL.

摘　　要：He et al.recently reported in Nature Communications1 the development of a protein vaccine against SASR-CoV-2 Omicron variant consisting of a trimer of the spike protein receptor-binding domain(RBD)of the Delta variant fused to heptad-repeat sequences 1 and 2.This vaccine induced broad-spectrum neutralizing antibodies and fully protected mice and non-human primates against challenge with live Delta and Omicron virus.

关 键 词：VACCINE vaccines 

分 类 号：R392[医药卫生—免疫学]